Floatz logo

Oxodotreotide

Digestive System Neuroendocrine Tumor G1

Vanderbilt-Ingram Cancer Centerprotein_peptidePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Digestive System Neuroendocrine Tumor G1 cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Mayo Clinic
Phase 2/3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3BB
Eloxatin
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2/3BB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BB

View all 44 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic neuroendocrine tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →